The rationale for development of the method for immunocapture of AML blast-derived exosomes from plasma of patients with CD34+ AML is based on existing evidence for selective ability of tumor-derived exosomes (TEX) to mediate immunosuppression [3]–[6]. Here, CD34 is linked to acute myeloid leukemia.